Drug intelligence / Profile preview

osoresnontrine

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

Osoresnontrine is a potent and selective small molecule inhibitor of phosphodiesterase 9A (PDE9A), developed by Boehringer Ingelheim. It is being investigated for the treatment of schizophrenia, Alzheimer's disease, and psychotic disorders. Preclinical studies suggest it may enhance memory in rodents. The drug has shown high selectivity for PDE9A (IC50 = 52 nM) with weak activity against other phosphodiesterases[3][6][7]. Its mechanism involves increasing intracellular cyclic GMP levels by inhibiting PDE9A, which may improve cognitive function[3][4][6].

Other names: Osoresnontrine [INN]O9OC34WOAYO-9OC34WOAYO 9OC34WOAYUNII-O9OC34WOAYUNII-O-9OC34WOAYUNII-O 9OC34WOAY

Targets

PDE9A (Phosphodiesterase 9A)

Beyond the preview

Go deeper on osoresnontrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on osoresnontrine.

Explore the full profile